Journal of Rheumatology最新文献_第10页

GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis? GRAPPA 观点与反观点：轻度银屑病是否应使用生物制剂？

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0655

Gretchen D Ball, Hassan Hamade, Alice B Gottlieb, Brian Kirby, Kristina Callis Duffin

{"title":"GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?","authors":"Gretchen D Ball, Hassan Hamade, Alice B Gottlieb, Brian Kirby, Kristina Callis Duffin","doi":"10.3899/jrheum.2024-0655","DOIUrl":"10.3899/jrheum.2024-0655","url":null,"abstract":"Psoriasis (PsO) is commonly classified as mild, moderate, or severe, usually based on body surface area (BSA) or other validated measures. Although most dermatologists agree that mild PsO should be treated with topical therapies, there are circumstances where mild or limited PsO should be treated with biologics, even as first line. A debate about use of topical vs biologic therapy was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting. Arguments in favor of using biologics when patients have mild disease on limited BSA included presence of psoriatic arthritis (PsA) and symptoms on special sites (ie, scalp, face, body folds, genitals, nails, palms, soles). New data suggest that treating limited or early PsO may decrease the risk of developing PsA. Arguments against using biologics for mild PsO focused on the definition of mild PsO, citing that limited BSA with PsA and significant quality of life impact should not be defined as mild. Truly mild PsO should be treated with topical agents, given their safety and relative low cost. The availability of newer agents like roflumilast and tapinarof have expanded therapeutic choice and have data supporting their use for treatment of special sites.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"39-42"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Debate at the GRAPPA 2023 Annual Meeting: Should Methotrexate Be the First Systemic Therapy in Psoriatic Disease? GRAPPA 2023 年会辩论：甲氨蝶呤是否应作为银屑病的首选系统疗法？

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0317

Arianna J Zhang, Joseph F Merola, William Tillett

引用次数: 0

GRAPPA 2023 Basic Science Workshop: What to Expect From Animal Models for Psoriatic Arthritis and Psoriasis. GRAPPA 2023 基础科学研讨会：对银屑病关节炎和银屑病动物模型的期待。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0258

Margot Van Mechelen, Siba P Raychaudhuri, Smriti K Raychaudhuri, Kurt de Vlam

{"title":"GRAPPA 2023 Basic Science Workshop: What to Expect From Animal Models for Psoriatic Arthritis and Psoriasis.","authors":"Margot Van Mechelen, Siba P Raychaudhuri, Smriti K Raychaudhuri, Kurt de Vlam","doi":"10.3899/jrheum.2024-0258","DOIUrl":"10.3899/jrheum.2024-0258","url":null,"abstract":"Animal models help to drive research into psoriasis and psoriatic arthritis (PsA), particularly when studies in humans are not feasible. There are no animal models that perfectly mimic psoriatic disease (PsD) and so the pros and cons of each existing model must be considered for appropriate experimental design. Roughly, the existing animal models for PsD can be divided into 4 categories: (1) spontaneous models, (2) transgenic models, (3) inducible models, and (4) xenotransplantation models. Animal models in PsD are extremely important for dissecting and understanding molecular mechanisms of the disease process and for developing novel drugs. Animal models remain highly valuable for research in PsD in 2 scenarios. The first scenario is when complex interventions or analyses are required that are not feasible in humans due to technical, safety, or economic reasons. The second is when well-controlled study environments are required, such as dietary modifications, that would be challenging in humans. This topic was presented as part of the basic science workshops during the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"31-32"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GRAPPA 2023: Major Projects, Key Advances, and Milestones. GRAPPA 2023：主要项目、关键进展和里程碑。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0266

Gizem Ayan, Sibel Z Aydin, Laura C Coates, Lihi Eder, Dafna D Gladman, Philip S Helliwell, Gurjit S Kaeley, Arthur Kavanaugh, Philip J Mease, Stephen R Pennington, Fabian Proft, Enrique R Soriano, Oliver FitzGerald

引用次数: 0

Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 Annual Meeting. 序言：银屑病和银屑病关节炎研究与评估小组（GRAPPA）2023 年年会。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0548

Dafna D Gladman, Oliver FitzGerald, April W Armstrong, Niti Goel, Alice B Gottlieb

{"title":"Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 Annual Meeting.","authors":"Dafna D Gladman, Oliver FitzGerald, April W Armstrong, Niti Goel, Alice B Gottlieb","doi":"10.3899/jrheum.2024-0548","DOIUrl":"10.3899/jrheum.2024-0548","url":null,"abstract":"The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting was held on July 13 to 15, 2023, in Dublin, Ireland, and was attended by 285 rheumatologists, dermatologists, trainees, patient research partners (PRPs), representatives of patient organizations, and industry partners. The 20th anniversary of GRAPPA was celebrated with a special presentation and archival video. Ahead of the meeting, the PRP Network met, a workshop was held by the International Dermatology Outcome Measures (IDEOM) group, and there was a workshop in which researchers discussed advancing ultrasound use to improve the management of psoriatic disease (PsD). Young-GRAPPA also held a workshop and business meeting. Multiple presentations highlighted important topics currently influencing PsD, including ensuring that patients are included in advancing research, the role of depression in PsD, the use of magnetic resonance imaging for spinal lesions, and animal models of PsD, among others. Debates focused on whether biologics should be used for mild psoriasis, whether methotrexate should remain the first-line treatment for PsD, and whether PsD is really a primary enthesitis driving joint synovitis. Here we provide an overview of the features of the GRAPPA 2023 annual meeting and introduce the manuscripts published together in this supplement as a meeting report.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"1-5"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting. GRAPPA 2023 年年会附设 IDEOM 会议报告。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0327

Gretchen D Ball, Danielle Yee, Arianna J Zhang, Lourdes M Perez-Chada, Vibeke Strand, Joseph F Merola, April W Armstrong, Alice B Gottlieb

{"title":"Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting.","authors":"Gretchen D Ball, Danielle Yee, Arianna J Zhang, Lourdes M Perez-Chada, Vibeke Strand, Joseph F Merola, April W Armstrong, Alice B Gottlieb","doi":"10.3899/jrheum.2024-0327","DOIUrl":"10.3899/jrheum.2024-0327","url":null,"abstract":"The nonprofit organization International Dermatology Outcome Measures (IDEOM) is committed to improving the implementation of patient-centered outcome measures in dermatologic disease. At a conference adjacent to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, the IDEOM Psoriatic Disease Workgroup presented updates on recent efforts in outcome measure advancement. Dr. Alice Gottlieb presented the preliminary findings of a study within the Mount Sinai Health System that aims to determine how well the IDEOM musculoskeletal (MSK) symptom framework, which uses the Psoriasis Epidemiology Screening Tool (PEST) and the Psoriatic Arthritis Impact of Disease (PsAID) instruments, functions in clinical settings. Drs. Joseph Merola and Lourdes Perez-Chada updated attendees on the IDEOM MSK-Q, a 9-item patient-reported questionnaire designed to measure the intensity and impact of MSK symptoms on the quality of life in patients with psoriasis (PsO) with or without psoriatic arthritis (PsA). Dr. Vibeke Strand summarized the Outcome Measures in Rheumatology (OMERACT) 2023 conference sessions. Dr. April Armstrong discussed the preliminary findings of a multicentered study designed to validate the 7-item Dermatology Treatment Satisfaction Instrument (DermSat-7) among patients with PsO. She also introduced the Psoriasis and Psoriatic Arthritis Treatment Satisfaction Instrument, a tool that seeks to capture the level of patient satisfaction with current therapy for PsO and PsA. This report summarizes the developments discussed at the IDEOM PsO and PsA research workgroups during the GRAPPA 2023 annual meeting.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"16-18"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spinal Lesions in Axial Psoriatic Disease: How Should They Be Identified and Quantified by Magnetic Resonance Imaging? 轴性银屑病的脊柱病变：如何通过磁共振成像识别和量化脊柱病变？

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0291

Mikkel Østergaard, Signe Møller-Bisgaard, Walter P Maksymowych

{"title":"Spinal Lesions in Axial Psoriatic Disease: How Should They Be Identified and Quantified by Magnetic Resonance Imaging?","authors":"Mikkel Østergaard, Signe Møller-Bisgaard, Walter P Maksymowych","doi":"10.3899/jrheum.2024-0291","DOIUrl":"10.3899/jrheum.2024-0291","url":null,"abstract":"Proper assessment of patients with psoriatic arthritis (PsA) requires assessment of all disease domains, including axial disease. Magnetic resonance imaging (MRI) is the method of choice for evaluating axial involvement in PsA. When assessing patients with PsA for spinal involvement, it is important to assess both vertebral body lesions and posterolateral lesions, such as inflammation in facet joints and costovertebral joints, and enthesitis at spinous and transverse processes. The Canada-Denmark (CanDen) assessment system for spine MRIs is the preferred method for detailed evaluation of inflammation and structural damage at various anatomical locations in the spine, and it is reproducible and sensitive to change. The Assessment of Spondyloarthritis international Society (ASAS) has recently published MRI definitions of inflammatory and structural lesions in the spine, incorporating the CanDen definitions of spinal lesions on MRI. Applying the ASAS definitions and the CanDen assessment system in clinical practice and trials is recommended. Ongoing research/studies, not least the Axial Involvement in Psoriatic Arthritis (AXIS) study, may provide a data-driven definition of axial involvement in PsA. Ongoing research is expected to further improve and validate assessment tools for axial PsA and to provide a much-needed data-driven consensus-based definition of axial involvement in PsA.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"25-30"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence That Good Life With Osteoarthritis in Denmark (GLA:D), an Exercise and Education Program, Is Beneficial for Osteoarthritis. 有证据表明，丹麦骨关节炎患者的美好生活（GLA:D）--一项运动和教育计划--对骨关节炎有益。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0721

Grace H Lo, Jeffrey B Driban

引用次数: 0

Stressed Healthcare Systems: The Impact on the Care of Patients With Rheumatic Diseases. 紧张的医疗保健系统：对风湿病患者护理的影响。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0755

Marina Scolnik

引用次数: 0

Calcium Pyrophosphate Crystals in a Child With Wilson Disease: An Ominous Sign or Incidental Finding? 威尔逊氏病患儿体内的焦磷酸钙结晶：不祥之兆还是偶然发现？